title: [Research update on PD-1/PD-L1 pathway in hematological diseases].
abstract: Cross-priming is an important mechanism to activate immune response, which includes two classical signal pathways. Co-stimulatory signals are essential in the effective activation and B7-family is considered to be one of the most important factor in immunotherapy. PD-L1 is a new member of B7 family, whose ligand is PD-1. PD-1/PD-L1 can down-regulate the activation of immune response, which has become a focus of research. This article reviewed the expression of PD-1/PD-L1 in normal tissue and tumor, focusing on the status of PD-1/PD-L1 pathway study in leukemia, lymphoma, multiple myeloma, aplastic anemia and so on, in order to provide a new way for treatment of hematologic diseases.
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
mesh_terms: D060890:B7-H1 Antigen / Q000378:metabolism*; D006402:Hematologic Diseases / Q000378:metabolism*; D006801:Humans; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor